However, for the CD40L/APRIL/BAFF stimulated CLL cells, we observed approximately 50% viability of CLL cells after treatment with 10 nM BGB-11417 and 60% viability after treatment with 10 nM venetoclax (Fig. 2j, k, pink lines). This evidence concerns the gene TNFSF13B and B-cell chronic lymphocytic leukemia.